Aubrye Harris-Foote

China PharmaHub Corp. ('PharmaHub') is a global pharmaceutical HUB specializing in the identification, development and marketing of pharmaceutical and healthcare products that make a significant difference to patients and society. Their corporate headquarters are located in California, with offices locations in Boston and China. In China, they have developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs. PharmaHub is engaged in the commercialization of promising China preclinical and clinical stage novel compounds into the global pharmaceutical markets; as well as bringing U.S. preclinical and clinical stage novel compounds into the China pharmaceutical market.

China PharmaHub Corp. ('PharmaHub') is a global pharmaceutical HUB specializing in the identification, development and marketing of pharmaceutical and healthcare products that make a significant difference to patients and society. Their corporate headquarters are located in California, with offices locations in Boston and China. In China, they have developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs. PharmaHub is engaged in the commercialization of promising China preclinical and clinical stage novel compounds into the global pharmaceutical markets; as well as bringing U.S. preclinical and clinical stage novel compounds into the China pharmaceutical market.

China PharmaHub Corp. ('PharmaHub') is a global pharmaceutical HUB specializing in the identification, development and marketing of pharmaceutical and healthcare products that make a significant difference to patients and society. Their corporate headquarters are located in California, with offices locations in Boston and China. In China, they have developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs. PharmaHub is engaged in the commercialization of promising China preclinical and clinical stage novel compounds into the global pharmaceutical markets; as well as bringing U.S. preclinical and clinical stage novel compounds into the China pharmaceutical market.